Patients with hormone receptor-positive (HR+ ) breast cancer resistant to hormonal and targeted therapies represent a large unmet clinical need1,2, given the lack effective treatments that extend survival beyond short-lived responses to successive lines of chemotherapy3. This evidence concerns the gene NR4A1 and breast carcinoma.